We selected 6 candidate tumors—bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD), since WDR62 was overexpressed in at least 3 different databases and also had potential prognostic value in at least 2 databases among these tumors (Figures 1(b) and 1(c)). This evidence concerns the gene WDR62 and invasive breast carcinoma.